## Martine De Vos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8903572/publications.pdf

Version: 2024-02-01

224 papers 24,254 citations

67 h-index 7518 151 g-index

227 all docs

227 docs citations

times ranked

227

26767 citing authors

#	Article	IF	CITATIONS
1	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology, 2021, 19, 1180-1188.e4.	4.4	12
2	Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology, 2021, 160, 145-157.e8.	1.3	109
3	P266 The impact of vedolizumab and ustekinumab on arthropathy and arthralgia in IBD patients: a real-life multicentric cohort study. Journal of Crohn's and Colitis, 2021, 15, S302-S302.	1.3	3
4	Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis. Nature Reviews Rheumatology, 2020, 16, 415-433.	8.0	106
5	Translational research into the effects of cigarette smoke on inflammatory mediators and epithelial TRPV1 in Crohn's disease. PLoS ONE, 2020, 15, e0236657.	2.5	3
6	Title is missing!. , 2020, 15, e0236657.		0
7	Title is missing!. , 2020, 15, e0236657.		O
8	Title is missing!. , 2020, 15, e0236657.		0
9	Title is missing!. , 2020, 15, e0236657.		O
10	Title is missing!. , 2020, 15, e0236657.		0
11			
11	Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies. Alimentary Pharmacology and Therapeutics, 2019, 50, 1204-1213.	3.7	11
12	presenting with back pain or peripheral arthropathies. Alimentary Pharmacology and Therapeutics,	1.3	11
	presenting with back pain or peripheral arthropathies. Alimentary Pharmacology and Therapeutics, 2019, 50, 1204-1213.  DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohn's disease: a multi-centre		
12	presenting with back pain or peripheral arthropathies. Alimentary Pharmacology and Therapeutics, 2019, 50, 1204-1213.  DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohn's disease: a multi-centre Belgian cohort study. Journal of Crohn's and Colitis, 2019, 13, S044-S045.  Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic	1.3	1
12	presenting with back pain or peripheral arthropathies. Alimentary Pharmacology and Therapeutics, 2019, 50, 1204-1213.  DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohn's disease: a multi-centre Belgian cohort study. Journal of Crohn's and Colitis, 2019, 13, S044-S045.  Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1401-1409.  Feasibility study using iodine quantification on dual-energy CT enterography to distinguish normal	1.3	92
12 13 14	presenting with back pain or peripheral arthropathies. Alimentary Pharmacology and Therapeutics, 2019, 50, 1204-1213.  DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohn's disease: a multi-centre Belgian cohort study. Journal of Crohn's and Colitis, 2019, 13, S044-S045.  Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1401-1409.  Feasibility study using iodine quantification on dual-energy CT enterography to distinguish normal small bowel from active inflammatory Crohn's disease. Acta Radiologica, 2019, 60, 679-686.  Ulcerative colitis treatment: an insight into daily clinical practice. Acta Gastro-Enterologica Belgica,	1.3 1.3 1.1	1 92 26
12 13 14	presenting with back pain or peripheral arthropathies. Alimentary Pharmacology and Therapeutics, 2019, 50, 1204-1213.  DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohn's disease: a multi-centre Belgian cohort study. Journal of Crohn's and Colitis, 2019, 13, S044-S045.  Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1401-1409.  Feasibility study using iodine quantification on dual-energy CT enterography to distinguish normal small bowel from active inflammatory Crohn's disease. Acta Radiologica, 2019, 60, 679-686.  Ulcerative colitis treatment: an insight into daily clinical practice. Acta Gastro-Enterologica Belgica, 2019, 82, 365-372.  Editorial: infliximab trough levels and histological healing in ulcerative colitis'a step towards	1.3 1.1 1.0	1 92 26

#	Article	IF	Citations
19	Analysis of Genes Associated With Monogenic Primary Immunodeficiency Identifies Rare Variants in XIAP in Patients With Crohn's Disease. Gastroenterology, 2018, 154, 2165-2177.	1.3	26
20	Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut, 2018, 67, 237-243.	12.1	119
21	Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterology Journal, 2018, 6, 439-445.	3.8	13
22	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nature Communications, 2018, 9, 2427.	12.8	159
23	Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice. Applied and Environmental Microbiology, 2017, 83, .	3.1	96
24	Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory conditions and dampens Crohn's disease-like ileitis. Laboratory Investigation, 2017, 97, 519-529.	3.7	34
25	An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Annals of the Rheumatic Diseases, 2017, 76, 878-881.	0.9	83
26	Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut, 2017, 66, 980-982.	12.1	56
27	T84 monolayers are superior to Caco-2 as a model system of colonocytes. Histochemistry and Cell Biology, 2017, 148, 85-93.	1.7	68
28	Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor. Gastroenterology, 2017, 153, 1054-1067.	1.3	94
29	Haematopoietic prolyl hydroxylaseâ€1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. Journal of Pathology, 2017, 241, 547-558.	4.5	32
30	Surveillance of Endoscopes: Comparison of Different Sampling Techniques. Infection Control and Hospital Epidemiology, 2017, 38, 1062-1069.	1.8	22
31	Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Scientific Reports, 2017, 7, 11450.	3.3	324
32	Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohnʽs Disease Registry (BELCRO). Inflammatory Bowel Diseases, 2017, 23, 1584-1591.	1.9	7
33	Reduced Mucosa-associated <i>Butyricicoccus</i> Activity in Patients with Ulcerative Colitis Correlates with Aberrant Claudin-1 Expression. Journal of Crohn's and Colitis, 2017, 11, 229-236.	1.3	109
34	Prevalence of CT features of axial spondyloarthritis in patients with Crohn's disease. Acta Radiologica, 2017, 58, 593-599.	1.1	6
35	Brief Report: <i>Dialister</i> as a Microbial Marker of Disease Activity in Spondyloarthritis. Arthritis and Rheumatology, 2017, 69, 114-121.	5.6	233
36	DOP047 Early fibrostenosis in Crohn's disease is associated with multiple susceptibility loci on Immunochip analysis. Journal of Crohn's and Colitis, 2017, 11, S54-S55.	1.3	0

#	Article	lF	Citations
37	Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn $\hat{E}^{1}\!\!/\!\!4$ s Disease. Inflammatory Bowel Diseases, 2016, 22, 505-515.	1.9	12
38	Paediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 253-258.	1.8	8
39	Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environmental Microbiology, 2016, 18, 1352-1363.	3.8	149
40	Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 1357-1362.	0.9	86
41	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 239-254.	1.3	577
42	Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design. FEMS Microbiology Reviews, 2016, 40, 117-132.	8.6	303
43	The Effect of Cigarette Smoke Exposure on the Development of Inflammation in Lungs, Gut and Joints of TNFΔARE Mice. PLoS ONE, 2015, 10, e0141570.	2.5	7
44	Interindividual differences in response to treatment with butyrate-producing Butyricicoccus pullicaecorum 25–3T studied in an in vitro gut model. FEMS Microbiology Ecology, 2015, 91, .	2.7	50
45	Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1. Journal of Biological Chemistry, 2015, 290, 4022-4037.	3.4	63
46	Fat accumulation in enterocytes: a key to the diagnosis of abetalipoproteinemia or homozygous hypobetalipoproteinemia. Endoscopy, 2015, 47, E223-E224.	1.8	2
47	Jejunal diverticular bleeding treated using cap-assisted enteroscopy: pulling the plug. Endoscopy, 2014, 46, E256-E257.	1.8	1
48	Factors associated with pregnancy outcome in antiâ€ <scp>TNF</scp> treated women with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 40, 363-373.	3.7	82
49	Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. Laboratory Investigation, 2014, 94, 1419-1430.	3.7	54
50	Long-Term Outcome of Enterocutaneous Fistula in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Cohort Study from the GETAID. American Journal of Gastroenterology, 2014, 109, 1443-1449.	0.4	63
51	Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Annals of the Rheumatic Diseases, 2014, 73, 1186-1189.	0.9	126
52	Optimal use of corticosteroids in gastroenterology and hepatology. Journal of Translational Internal Medicine, 2014, 2, 53-58.	2.5	2
53	Hand-held fractional exhaled nitric oxide measurements as a non-invasive indicator of systemic inflammation in Crohn's disease. Journal of Crohn's and Colitis, 2013, 7, 644-648.	1.3	12
54	Câ€ANCA/Proteinase 3–Positive Colitis in Children. Journal of Pediatric Gastroenterology and Nutrition, 2013, 57, 489-492.	1.8	10

#	Article	IF	Citations
55	Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Annals of the Rheumatic Diseases, 2013, 72, 414-417.	0.9	230
56	Osteoarticular Manifestations: Specific Treatments and/or Treating Intestinal Disease?. Digestive Diseases, 2013, 31, 239-243.	1.9	5
57	Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy. Inflammatory Bowel Diseases, 2013, 19, 2111-2117.	1.9	178
58	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet, The, 2012, 380, 1909-1915.	13.7	517
59	Intestinal metaplasia and colonization of endometriosis in a case of an appendiceal mucinous neoplasm. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 227-229.	2.8	19
60	Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	27.8	4,038
61	Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na $\tilde{A}$ ve patients with ulcerative colitis. Journal of Crohn's and Colitis, 2012, 6, 557-562.	1.3	129
62	Intrarectal Nitric Oxide Administration Prevents Cellular Infiltration but Not Colonic Injury During Dextran Sodium Sulfate Colitis. Digestive Diseases and Sciences, 2012, 57, 1832-1837.	2.3	4
63	Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiology Ecology, 2012, 79, 685-696.	2.7	111
64	Multiple myeloma presenting as hepatic nodular lesion. Acta Clinica Belgica, 2012, 67, 378-80.	1.2	3
65	Inverse correlation between metallothioneins and hypoxia-inducible factor 1 alpha in colonocytes and experimental colitis. Biochemical and Biophysical Research Communications, 2011, 416, 307-312.	2.1	14
66	Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clinical Biochemistry, 2011, 44, 1062-1066.	1.9	36
67	Novel development in extraintestinal manifestations and spondylarthropathy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, S19-S26.	2.4	11
68	Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nature Genetics, 2011, 43, 43-47.	21.4	175
69	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 2011, 43, 246-252.	21.4	1,201
70	Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology, 2011, 53, 1629-1640.	7.3	78
71	Longitudinal quantification of inflammation in the murine dextran sodium sulfate-induced colitis model using $\hat{1}$ 4PET/CT1. Inflammatory Bowel Diseases, 2011, 17, 2058-2064.	1.9	26
72	Boosting the hypoxia-induced adaptive response in inflammatory bowel disease: A novel concept of treatment. Inflammatory Bowel Diseases, 2011, 17, 2019-2022.	1.9	4

#	Article	IF	CITATIONS
73	Intrarectal administration of oxygenated perfluorodecalin promotes healing of murine colitis by targeting inflammatory hypoxia. Laboratory Investigation, 2011, 91, 1266-1276.	3.7	12
74	Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype. Annals of the Rheumatic Diseases, 2011, 70, 2044-2048.	0.9	18
75	Involvement of Endoplasmic Reticulum Stress in Inflammatory Bowel Disease: A Different Implication for Colonic and Ileal Disease?. PLoS ONE, 2011, 6, e25589.	2.5	63
76	Detrimental shifts in microbial communities from inflammatory bowel disease patients upon selective pressures. Communications in Agricultural and Applied Biological Sciences, 2011, 76, 49-52.	0.0	0
77	Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2010, 22, 494-499.	1.6	36
78	Invariant natural killer T cells are natural regulators of murine spondylarthritis. Arthritis and Rheumatism, 2010, 62, 988-999.	6.7	47
79	Measurement of porto-systemic shunting in mice by novel three-dimensional micro-single photon emission computed tomography imaging enabling longitudinal follow-up. Liver International, 2010, 30, 1211-1220.	3.9	6
80	Absence of placental growth factor blocks dextran sodium sulfate-induced colonic mucosal angiogenesis, increases mucosal hypoxia and aggravates acute colonic injury. Laboratory Investigation, 2010, 90, 566-576.	3.7	37
81	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	21.4	2,284
82	Evidence for Significant Overlap between Common Risk Variants for Crohn's Disease and Ankylosing Spondylitis. PLoS ONE, 2010, 5, e13795.	2.5	51
83	Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. Journal of Medical Microbiology, 2010, 59, 141-143.	1.8	164
84	Hydroxylase Inhibition Abrogates TNF-α–Induced Intestinal Epithelial Damage by Hypoxia-Inducible Factor-1–Dependent Repression of FADD. Journal of Immunology, 2010, 185, 6306-6316.	0.8	67
85	Joint involvement in inflammatory bowel disease: managing inflammation outside the digestive system. Expert Review of Gastroenterology and Hepatology, 2010, 4, 81-89.	3.0	4
86	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. Journal of Crohn's and Colitis, 2010, 4, 63-101.	1.3	695
87	Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Annals of the Rheumatic Diseases, 2010, 69, 618-623.	0.9	125
88	Impact of reimbursement policy in Belgium on the referral pattern and diagnostic yield of capsule endoscopy. A single-centre study. Acta Gastro-Enterologica Belgica, 2010, 73, 437-40.	1.0	0
89	Effects of vagus nerve stimulation on pro- and anti-inflammatory cytokine induction in patients with refractory epilepsy. Journal of Neuroimmunology, 2009, 214, 104-108.	2.3	69
90	Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflammatory Bowel Diseases, 2009, 15, 1044-1048.	1.9	54

#	Article	IF	Citations
91	P290 - Absence of placental growth factor aggravates DSS-induced acute colonic injury. Journal of Crohn's and Colitis, 2009, 3, S124-S125.	1.3	1
92	Joint Involvement Associated with Inflammatory Bowel Disease. Digestive Diseases, 2009, 27, 511-515.	1.9	26
93	Influence of somatostatin and octreotide on liver microcirculation in an experimental mouse model of cirrhosis studied by intravital fluorescence microscopy. Liver International, 2008, 28, 107-116.	3.9	14
94	Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. Inflammatory Bowel Diseases, 2008, 14, 471-479.	1.9	16
95	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics, 2008, 40, 955-962.	21.4	2,422
96	Expression of T cell receptors $\hat{l}\pm\hat{l}^2$ and $\hat{l}^3\hat{l}'$ in the ileal mucosa of patients with Crohn's disease and with spondylarthropathy. Clinical and Experimental Immunology, 2008, 90, 275-279.	2.6	24
97	Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. International Journal of Experimental Pathology, 2008, 89, 251-263.	1.3	79
98	An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis. International Journal of Experimental Pathology, 2008, 89, 419-432.	1.3	36
99	Spondyloarthropathies: progress and challenges. Best Practice and Research in Clinical Rheumatology, 2008, 22, 325-337.	3.3	3
100	Capsule endoscopy findings in cirrhosis with portal hypertension: A prospective study. Digestive and Liver Disease, 2008, 40, 392-393.	0.9	8
101	Clinical impact of capsule endoscopy on further strategy and long-term clinical outcome in patients with obscure bleeding. Gastrointestinal Endoscopy, 2008, 68, 98-104.	1.0	71
102	Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet, The, 2008, 371, 660-667.	13.7	1,135
103	Rapamycin prevents mesenteric neoâ€angiogenesis and reduces splanchnic blood flow in portal hypertensive mice. Hepatology Research, 2008, 38, 1130-1139.	3.4	14
104	Expression of SGLT1, Bcl-2 and p53 in Primary Pancreatic Cancer Related to Survival. Cancer Investigation, 2008, 26, 852-859.	1.3	65
105	Epstein-Barr virus related lymphoma in inflammatory bowel disease. Acta Gastro-Enterologica Belgica, 2008, 71, 33-5.	1.0	4
106	Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut, 2007, 56, 1404-1409.	12.1	157
107	The intimate relationship between gut and joint in spondyloarthropathies. Current Opinion in Rheumatology, 2007, 19, 353-357.	4.3	19
108	Extrapancreatic Inflammation on Abdominal Computed Tomography as an Early Predictor of Disease Severity in Acute Pancreatitis. Pancreas, 2007, 34, 185-190.	1.1	99

#	Article	IF	Citations
109	Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: An in vivo study. Journal of Hepatology, 2007, 46, 804-815.	3.7	5
110	Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis. Journal of Crohn's and Colitis, $2007$ , $1$ , $21-27$ .	1.3	4
111	Novel Crohn Disease Locus Identified by Genome-Wide Association Maps to a Gene Desert on 5p13.1 and Modulates Expression of PTGER4. PLoS Genetics, 2007, 3, e58.	3.5	506
112	Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine a in patients with steroid resistant ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 19-23.	1.9	32
113	Clinical and genetic factors associated with sacroiliitis in Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2007, 23, 070827235605003-???.	2.8	54
114	Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastro-Enterologica Belgica, 2007, 70, 15-9.	1.0	17
115	Immunogenicity of infliximab: how to handle the problem?. Acta Gastro-Enterologica Belgica, 2007, 70, 163-70.	1.0	15
116	Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver International, 2006, 26, 889-898.	3.9	65
117	Altered gut transcriptome in spondyloarthropathy. Annals of the Rheumatic Diseases, 2006, 65, 1293-1300.	0.9	21
118	<i>CARD15</i> polymorphisms are associated with anti- <i>Saccharomyces cerevisiae</i> antibodies in caucasian Crohn's disease patients. Clinical and Experimental Immunology, 2005, 140, 354-359.	2.6	30
119	CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Annals of the Rheumatic Diseases, 2005, 64, 930-935.	0.9	79
120	Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Annals of the Rheumatic Diseases, 2005, 64, 321-324.	0.9	72
121	Spondyloarthropathy and Gut Inflammation. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, S736-S737.	1.8	0
122	Association between polymorphism in IgG Fc receptor Illa coding gene and biological response to infliximab in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2004, 19, 511-519.	3.7	198
123	Joint involvement in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2004, 20, 36-42.	3.7	48
124	Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2004, 20, 607-614.	3.7	74
125	INFECTIOUS COMPLICATIONS OF ACUTE PANCREATITIS. Acta Clinica Belgica, 2004, 59, 90-96.	1.2	21
126	Outcome of acute nonvariceal gastrointestinal haemorrhage after nontherapeutic arteriography compared with embolization. European Radiology, 2003, 13, 2604-2614.	4.5	25

#	Article	IF	CITATIONS
127	Cholestasis as presenting symptom of portal cavernoma. Hepatology Research, 2003, 25, 32-37.	3.4	10
128	Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Annals of the Rheumatic Diseases, 2003, 62, 455-459.	0.9	70
129	Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy. Dermatology, 2003, 206, 388-390.	2.1	152
130	Influence of posture on haemodynamics, sodium and hormonal homeostasis in cirrhotic patients with and without ascites. Acta Gastro-Enterologica Belgica, 2003, 66, 206-12.	1.0	0
131	Treatment of acute diarrhoea: update of guidelines based on a critical interuniversity assessment of medications and current practices. Acta Gastro-Enterologica Belgica, 2003, 66, 218-26.	1.0	1
132	Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. American Journal of Gastroenterology, 2002, 97, 1458-1462.	0.4	136
133	In vitro evaluation of motilin agonism by macrolide immunosuppressive drugs. Nephrology Dialysis Transplantation, 2002, 17, 973-977.	0.7	7
134	Gastric emptying of solids in cirrhotic and peritoneal dialysis patients: influence of peritoneal volume load. European Journal of Gastroenterology and Hepatology, 2002, 14, 395-398.	1.6	32
135	BILIARY COMPLICATIONS OF LARGE < i>ECHINOCOCCUS GRANULOSUS < /i>CYSTS:. Acta Clinica Belgica, 2002, 57, 349-354.	1.2	8
136	Gut inflammation and spondyloarthropathies. Current Rheumatology Reports, 2002, 4, 525-532.	4.7	64
137	Campylobacter-associated Guillain–Barré syndrome after orthotopic liver transplantation for hepatitis C cirrhosis: a case report. Hepatology Research, 2002, 24, 205-211.	3.4	10
138	Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients. Alimentary Pharmacology and Therapeutics, 2002, 16, 1555-1562.	3.7	4
139	The 13C-octanoic acid breath test: validation of a new noninvasive method of measuring gastric emptying in rats. Neurogastroenterology and Motility, 2002, 14, 287-293.	3.0	29
140	Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. Journal of Pathology, 2002, 196, 343-350.	4.5	171
141	Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. Journal of Pathology, 2002, 198, 517-522.	4.5	37
142	Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. American Journal of Gastroenterology, 2002, 97, 2357-2363.	0.4	203
143	A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scandinavian Journal of Gastroenterology, 2002, 37, 818-24.	1.5	68
144	Standard and innovative therapy of inflammatory bowel diseases. Clinical and Experimental Rheumatology, 2002, 20, S95-100.	0.8	1

#	Article	IF	Citations
145	Factors influencing ribavirin-induced hemolysis. Journal of Hepatology, 2001, 34, 911-916.	3.7	97
146	Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. Journal of Hepatology, 2001, 35, 707-711.	3.7	66
147	Association between Cys282Tyr missense mutation and haptoglobin phenotype polymorphism in patients with chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2001, 13, 1077-1081.	1.6	9
148	The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clinical and Experimental Immunology, 2001, 125, 383-390.	2.6	44
149	Interpretation of ileal biopsies: morphological features in normal and diseased mucosa. Histopathology, 2001, 38, 1-12.	2.9	67
150	Influence of low-dose oral contraceptives, alcohol, and grapefruit on. Digestive Diseases and Sciences, 2001, 46, 133-139.	2.3	14
151	Embolization as a First Approach with Endoscopically Unmanageable Acute Nonvariceal Gastrointestinal Hemorrhage. Radiology, 2001, 218, 739-748.	7.3	192
152	Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Annals of the Rheumatic Diseases, 2001, 60, 750-755.	0.9	86
153	Living related adult-to-adult liver transplantation: which patient should benefit from this technique?. Acta Gastro-Enterologica Belgica, 2001, 64, 6-8.	1.0	0
154	Dyspepsia and gastric emptying in chronic renal failure patients. Clinical Nephrology, 2001, 56, 302-7.	0.7	17
155	Focal Up-Regulation of E-Cadherin-Catenin Complex in Inflamed Bowel Mucosa but Reduced Expression in Ulcer-Associated Cell Lineage. American Journal of Clinical Pathology, 2000, 114, 364-370.	0.7	54
156	Chemical agents and enzymes used for the extraction of gut lymphocytes influence flow cytometric detection of T cell surface markers. Journal of Immunological Methods, 2000, 236, 27-35.	1.4	38
157	Postoperative findings following the Whipple procedure: determination of prevalence and morphologic abdominal CT features. European Radiology, 2000, 10, 123-128.	4.5	59
158	Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflammation Research, 2000, 49, 47-54.	4.0	19
159	Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Annals of the Rheumatic Diseases, 2000, 59, 211-216.	0.9	46
160	Delayed gastric emptying in dyspeptic chronic hemodialysis patients. American Journal of Kidney Diseases, 2000, 36, 962-968.	1.9	95
161	Crohn's disease associated with spondyloarthropathy: effect of TNF- $\hat{l}_{\pm}$ blockade with infliximab on articular symptoms. Lancet, The, 2000, 356, 1821-1822.	13.7	226
162	Value of MR cholangiography in the evaluation of postoperative biliary complications following orthotopic liver transplantation. European Radiology, 2000, 10, 1576-1581.	4.5	43

#	Article	IF	CITATIONS
163	Clinical Pharmacokinetics of Slow Release Mesalazine. Clinical Pharmacokinetics, 2000, 39, 85-97.	3.5	26
164	Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. Journal of Rheumatology, 2000, 27, 2860-5.	2.0	167
165	Acute Lower Gastrointestinal Bleeding in Crohn's Disease: Characteristics of A Unique Series of 34 Patients. American Journal of Gastroenterology, 1999, 94, 2177-2181.	0.4	93
166	Severe bleeding following endoscopic variceal ligation: should EVL be avoided in Child C patients?. Acta Gastro-Enterologica Belgica, 1999, 62, 175-7.	1.0	3
167	Non-steroidal antiinflammatory drugs and the intestine. Acta Gastro-Enterologica Belgica, 1999, 62, 425-7.	1.0	0
168	Jejunal arteriovenous malformation, diagnosed by angiography and treated by embolization and catheter-guided surgery: case report and review of literature. Abdominal Imaging, 1998, 23, 127-131.	2.0	10
169	Multiple Primary Malignant Tumors in Patients With Head and Neck Cancer. Laryngoscope, 1998, 108, 250-256.	2.0	126
170	Bone and joint diseases in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 1998, 12, 397-404.	3.7	28
171	BOWEL INFLAMMATION AND THE SPONDYLOARTHROPATHIES. Rheumatic Disease Clinics of North America, 1998, 24, 785-813.	1.9	103
172	Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. Journal of Rheumatology, 1998, 25, 1932-7.	2.0	46
173	Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastro-Enterologica Belgica, 1998, 61, 288-94.	1.0	10
174	Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastro-Enterologica Belgica, 1997, 60, 197-200.	1.0	3
175	Fundic gland polyps: three other case reports suggesting a possible association with acid suppressing therapy. Acta Gastro-Enterologica Belgica, 1997, 60, 240-2.	1.0	5
176	Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology, 1996, 110, 1696-1703.	1.3	188
177	The Role of Gut Inflammation in the Pathogenesis of Spondyloarthropathies. Acta Clinica Belgica, 1996, 51, 340-349.	1.2	24
178	Distribution and concentrations of 5-aminosalicylic acid in rectosigmoid biopsy specimens after rectal administration. Diseases of the Colon and Rectum, 1996, 39, 788-793.	1.3	8
179	Spondylarthropathies: from gut to target organs. Bailliere's Clinical Rheumatology, 1996, 10, 123-146.	1.0	4
180	Course of gut inflammation in spondylarthropathies and therapeutic consequences. Bailliere's Clinical Rheumatology, 1996, 10, 147-164.	1.0	91

#	Article	IF	Citations
181	Panendoscopy as a screening procedure for simultaneous primary tumors in head and neck cancer. European Archives of Oto-Rhino-Laryngology, 1996, 253, 319-324.	1.6	22
182	Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. Journal of Rheumatology, 1995, 22, 680-3.	2.0	59
183	Is endoscopic surveillance worthwhile in IBD?. Acta Gastro-Enterologica Belgica, 1995, 58, 405-8.	1.0	0
184	The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. Journal of Rheumatology, 1995, 22, 2266-72.	2.0	94
185	The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. Journal of Rheumatology, 1995, 22, 2273-8.	2.0	150
186	The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. Journal of Rheumatology, 1995, 22, 2279-84.	2.0	136
187	M-cells are damaged and increased in number in inflamed human ileal mucosa. Histopathology, 1994, 24, 417-426.	2.9	53
188	Idiopathic inflammatory bowel diseases: immunological hypothesis. Acta Gastro-Enterologica Belgica, 1994, 57, 292-9.	1.0	0
189	Results of extracorporeal shock wave lithotripsy of gall bladder stones in 693 patients: a plea for restriction to solitary radiolucent stones Gut, 1993, 34, 274-278.	12.1	25
190	Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy—a prospective study. Journal of Rheumatology, 1993, 20, 1567-72.	2.0	60
191	A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. Journal of Rheumatology, 1993, 20, 1353-8.	2.0	44
192	M cells are damaged and increased in number in inflamed human ileal mucosa. European Journal of Morphology, 1993, 31, 87-91.	0.8	10
193	Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations Gut, 1992, 33, 1338-1342.	12.1	86
194	Brain abscess after esophageal dilatation for stenosis. Clinical Neurology and Neurosurgery, 1992, 94, 169-172.	1.4	11
195	5.5 T-cell receptors in ileal mucosal biopsies of patients with Crohn disease and spondylarthropathy. Progress in Histochemistry and Cytochemistry, 1992, 26, 211-217.	5.1	0
196	Spondylarthropathy and gut inflammation: immunopathogenetic mechanisms. International Journal of Tissue Reactions, 1992, 14, 203-9.	0.2	1
197	Le systà me immunitaire intestinal. Acta Endoscopica, 1991, 21, 215-218.	0.0	1
198	Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. Journal of Rheumatology, 1991, 18, 1542-51.	2.0	100

#	Article	IF	Citations
199	Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs. Journal of Rheumatology, 1991, 18, 389-93.	2.0	32
200	Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease. Journal of Rheumatology, 1991, 18, 394-400.	2.0	57
201	Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy Gut, 1990, 31, 545-549.	12.1	30
202	Articular diseases and the gut: evidence for a strong relationship between spondylarthropathy and inflammation of the gut in man. Acta Clinica Belgica, 1990, 45, 20-4.	1.2	0
203	lleal mucosal mononuclear cells in patients with seronegative spondylarthropathy. Clinical and Experimental Rheumatology, 1990, 8, 137-43.	0.8	2
204	HLA-B27 positive idiopathic acute anterior uveitis: a unique manifestation of subclinical gut inflammation. Journal of Rheumatology, 1990, 17, 841-2.	2.0	13
205	Lymphoepithelial interactions in human terminal ileum and colon: Electron-microscopic findings in normal and inflamed mucosa. Micron and Microscopica Acta, 1989, 20, 121-123.	0.2	1
206	lleocolonoscopy in Seronegative Spondylarthropathy. Gastroenterology, 1989, 96, 339-344.	1.3	152
207	Crohn's disease with adenocarcinoma and dysplasia. Macroscopical, histological, and immunohistochemical aspects of two cases. American Journal of Surgical Pathology, 1989, 13, 187-96.	3.7	7
208	Subclinical involvement of the gut in undifferentiated spondylarthropathies. Clinical and Experimental Rheumatology, 1989, 7, 499-504.	0.8	25
209	Congenital hepatic fibrosis. Journal of Hepatology, 1988, 6, 222-228.	3.7	68
210	Immunoglobulin containing cells in terminal ileum and colorectum of patients with arthritis related gut inflammation Gut, 1988, 29, 916-925.	12.1	26
211	Endoscopic Sclerotherapy: The Value of Balloon Tamponade and the Importance of Disinfection. Endoscopy, 1988, 20, 48-51.	1.8	7
212	Histopathology of intestinal inflammation related to reactive arthritis Gut, 1987, 28, 394-401.	12.1	167
213	Influence Of Injection Sclerotherapy Of Oesophageal Varices In Liver Cirrhosis On The Haemostatic System. Acta Clinica Belgica, 1987, 42, 177-180.	1.2	0
214	Repeat ileocolonoscopy in reactive arthritis. Journal of Rheumatology, 1987, 14, 456-8.	2.0	30
215	Late onset pauciarticular juvenile chronic arthritis: relation to gut inflammation. Journal of Rheumatology, 1987, 14, 459-65.	2.0	28
216	HLA antigens in seronegative spondylarthropathies. Reactive arthritis and arthritis in ankylosing spondylitis: relation to gut inflammation. Journal of Rheumatology, 1987, 14, 466-71.	2.0	43

#	Article	IF	CITATIONS
217	Le traitement par prothà se biliaire des cholà © docholithiases impactà © es. Acta Endoscopica, 1986, 16, 273-276.	0.0	1
218	Les migrations lithiasiques spontanées. Acta Endoscopica, 1986, 16, 257-262.	0.0	2
219	Coagulation Parameters after Sclerotherapy. Endoscopy, 1986, 18, 168-168.	1.8	1
220	Familial aggregation in seronegative spondyloarthritis of enterogenic origin. A family study. Journal of Rheumatology, 1986, 13, 126-8.	2.0	11
221	HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. Journal of Rheumatology, 1985, 12, 294-8.	2.0	104
222	Fistule aorto-duodénale — RÃ1e de l'endoscopie. Acta Endoscopica, 1984, 14, 103-109.	0.0	1
223	Macroscopic and histological changes of the ileum HLA-B27 related diseases: therapeutic consequences. International Journal of Clinical Pharmacology Research, 1984, 4, 409-14.	0.4	1
224	Observations on the Association Between Adrenal Cysts and Hypertension. Acta Clinica Belgica, 1983, 38, 333-337.	1.2	3